KALV vs. SLRN, OCS, CALT, ABUS, PAHC, TBPH, ALT, TVTX, LRMR, and IGMS
Should you be buying KalVista Pharmaceuticals stock or one of its competitors? The main competitors of KalVista Pharmaceuticals include Acelyrin (SLRN), Oculis (OCS), Calliditas Therapeutics AB (publ) (CALT), Arbutus Biopharma (ABUS), Phibro Animal Health (PAHC), Theravance Biopharma (TBPH), Altimmune (ALT), Travere Therapeutics (TVTX), Larimar Therapeutics (LRMR), and IGM Biosciences (IGMS). These companies are all part of the "pharmaceutical preparations" industry.
Acelyrin (NASDAQ:SLRN) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.
Acelyrin currently has a consensus target price of $23.67, indicating a potential upside of 414.49%. KalVista Pharmaceuticals has a consensus target price of $26.33, indicating a potential upside of 134.91%. Given KalVista Pharmaceuticals' higher probable upside, research analysts clearly believe Acelyrin is more favorable than KalVista Pharmaceuticals.
87.3% of Acelyrin shares are owned by institutional investors. 12.3% of KalVista Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, KalVista Pharmaceuticals had 4 more articles in the media than Acelyrin. MarketBeat recorded 7 mentions for KalVista Pharmaceuticals and 3 mentions for Acelyrin. Acelyrin's average media sentiment score of 0.94 beat KalVista Pharmaceuticals' score of 0.18 indicating that KalVista Pharmaceuticals is being referred to more favorably in the news media.
KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Acelyrin, indicating that it is currently the more affordable of the two stocks.
KalVista Pharmaceuticals' return on equity of -50.56% beat Acelyrin's return on equity.
KalVista Pharmaceuticals received 318 more outperform votes than Acelyrin when rated by MarketBeat users. Likewise, 73.81% of users gave KalVista Pharmaceuticals an outperform vote while only 56.25% of users gave Acelyrin an outperform vote.
Summary
KalVista Pharmaceuticals beats Acelyrin on 8 of the 14 factors compared between the two stocks.
Get KalVista Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KALV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
KalVista Pharmaceuticals Competitors List
Related Companies and Tools
